4dx share price forecast

Through its flagship patented XV Technology, the 4dx share price forecast enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This share price information is delayed by 15 minutes. The overall consensus recommendation for 4DMedical is Buy. You can view the full broker recommendation list by unlocking its StockReport.

March 5, James Mickleboro. The latest member of the All Ordinaries index is getting some love this week. January 22, James Mickleboro. December 22, James Mickleboro. Analysts have put buy ratings on these small caps and see big potential returns. December 5, James Mickleboro.

4dx share price forecast

About the company. Stable Share Price: 4DX's share price has been volatile over the past 3 months. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lungs ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent , a small animal ventilator. Trading at Revenue is forecast to grow Analysts in good agreement that stock price will rise by Currently unprofitable and not forecast to become profitable over the next 3 years. Shareholders have been diluted in the past year. New minor risk - Profitability Feb No longer forecast to breakeven Feb Dec See more updates Recent updates. No longer forecast to breakeven Dec Forecast to breakeven in Nov

Forecast to breakeven in Nov

The 4Dmedical Ltd stock price is 0. The 4DX stock price can go up from 0. The 4DX "4DX" future stock price will be 1. According to our analysis, this will not happen. Not within a year. See above. For example 1.

Key events shows relevant news articles on days with large price movements. Imugene Ltd. IMU 0. Pro Medicus Limited. PME 1. Dimerix Ltd. DXB 1. EBR Systems Inc. EBR 2.

4dx share price forecast

March 5, James Mickleboro. The latest member of the All Ordinaries index is getting some love this week. January 22, James Mickleboro.

8pm ct to est

The company's non-invasive lung imaging technology emanates from research work undertaken at Monash University. See above. Earnings growth rate. Mr Julian Sutton began his career as an actuarial analyst for Towers Perrin in Melbourne where he consulted to some of Australia's largest superannuation funds. At Walletinvestor. The 4DMedical PE ratio based on its reported earnings over the past 12 months is null. Aug November 20, James Mickleboro. Price to Book Value. Oct It commercializes XV Technology, a four-dimensional lung imaging technology. Highest and lowest possible predicted price in a 14 day period. Forecast to breakeven in Nov Dec

EPS is expected to grow by

Today's Open. Forecast to breakeven in Aug Dec May 4, Monica O'Shea. Earnings growth rate. High number of new directors Jun Open: 1. Shareholders have been diluted in the past year. These measurements are then visualized as a coloured heat map to help medical professionals accurately identify ventilation deficits. Issue of options.